Table 2.

Vaccine efficacy as a function of sex, age at vaccination and at time of bomb, and radiation dose.

Characteristic	Vaccine success (seroprotection for ≥1 antigen)	Vaccine failure (seroprotection for NO antigens)	p-value
Sex
Female	120 (62%)	75 (38%)	0.01
Male	75 (77%)	22 (23%)
Age at vaccination
Median (range)	79 (66–89)	81 (67–89)	0.44
<75 y.o.	55 (65%)	29 (35%)	0.87
75+ y.o.	140 (67%)	68 (33%)
Age at time of bomb
Median (range)	13.4 (0.5–23.2)	14.3 (0.1–23.6)	0.54
<12 y.o.	78 (70%)	33 (39%)	0.39
12+ y.o.	117 (65%)	64 (35%)
Dose
Median (range)	110 (0–3496)	81 (0–2553)	0.94
<5 mGy	80 (68%)	38 (32%)	0.2
5 to <500 mGy	57 (67%)	28 (33%)
500 to <1000 mGy	24 (55%)	20 (45%)
1000+ mGy	34 (76%)	11 (24%)
<1000 mGy	161 (65%)	86 (35%)	0.24
1000+ mGy	34 (76%)	11 (24%)